Assignee profile:

VEROSCIENCE LLC

City:

Tiverton, Rhode Island

Country:

United States

Published Applications:

43

Last publication date:

2024-04-25

Patent Grants:

41

Last grant date:

2026-05-05

Top Inventors for applications by VEROSCIENCE LLC

These are the the leading inventors for applications assigned to VEROSCIENCE LLC:

Recent patent applications by VEROSCIENCE LLC

VEROSCIENCE LLC based in Tiverton, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2024-04-25 ✅ Patent 12,616,693 granted on 2026-05-05
US20240131026A1
Human necessities

BROMOCRIPTINE FORMULATIONS

#2 | 2023-10-12 ✅ Patent 12,274,698 granted on 2025-04-15
US20230321090A1
Human necessities

Bromocriptine formulations

#3 | 2023-08-24 ✅ Patent 12,318,451 granted on 2025-06-03
US20230263892A1
Human necessities

Method for inducing tumor regression

#4 | 2023-05-18 ✅ Patent 12,492,198 granted on 2025-12-09
US20230150999A1
Chemistry; metallurgy

Composition and Method for Treating Metabolic Disorders

#5 | 2022-09-15 ✅ Patent 12,357,693 granted on 2025-07-15
US20220288209A1
Human necessities

METHOD FOR INDUCING TUMOR REGRESSION

#6 | 2022-08-25 ✅ Patent 11,883,399 granted on 2024-01-30
US20220265648A1
Human necessities

Bromocriptine formulations

#7 | 2021-07-29 ✅ Patent 11,666,567 granted on 2023-06-06
US20210228576A1
Human necessities

Bromocriptine formulations

#8 | 2021-06-17 ✅ Patent 11,510,921 granted on 2022-11-29
US20210177839A1
Human necessities

Bromocriptine formulations

#9 | 2021-05-06 ✅ Patent 11,878,974 granted on 2024-01-23
US20210130344A1
Chemistry; metallurgy

Composition and method for treating metabolic disorders

#10 | 2021-04-01 ✅ Patent 11,560,375 granted on 2023-01-24
US20210094946A1
Chemistry; metallurgy

Composition and method for treating metabolic disorders

#11 | 2021-03-25 ✅ Patent 11,607,455 granted on 2023-03-21
US20210085787A1
Human necessities

Method for inducing tumor regression

#12 | 2020-09-03 ✅ Patent 11,000,522 granted on 2021-05-11
US20200276193A1
Human necessities

Bromocriptine formulations

#13 | 2020-08-13 ✅ Patent 11,241,429 granted on 2022-02-08
US20200253970A1
Human necessities

Method of treating metabolic disorders and depression with dopamine receptor agonists

#14 | 2019-11-14 ✅ Patent 10,688,094 granted on 2020-06-23
US20190343833A1
Human necessities

Bromocriptine formulations

#15 | 2019-06-06 ✅ Patent 10,675,282 granted on 2020-06-09
US20190167677A1
Human necessities

Method of treating metabolic disorders and depression with dopamine receptor agonists

#16 | 2018-09-20 ✅ Patent 10,307,421 granted on 2019-06-04
US20180263978A1
Human necessities

Bromocriptine formulations

#17 | 2018-05-24 ✅ Patent 10,688,155 granted on 2020-06-23
US20180140675A1
Human necessities

Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

#18 | 2018-05-10 ✅ Patent 10,238,653 granted on 2019-03-26
US20180125843A1
Human necessities

Method of treating metabolic disorders and depression with dopamine receptor agonists

#19 | 2018-02-22 ✅ Patent 10,894,791 granted on 2021-01-19
US20180051019A1
Chemistry; metallurgy

Composition and method for treating metabolic disorders

#20 | 2017-11-30 ✅ Patent 9,993,474 granted on 2018-06-12
US20170340632A1
Human necessities

Bromocriptine formulations

#21 | 2017-01-26 ✅ Patent 9,700,555 granted on 2017-07-11
US20170020871A1
Human necessities

Bromocriptine formulations

#22 | 2016-11-10 ✅ Patent 11,045,464 granted on 2021-06-29
US20160324848A1
Human necessities

Parenteral formulations of dopamine agonists

#23 | 2016-09-22 ✅ Patent 9,895,422 granted on 2018-02-20
US20160271222A1
Human necessities

Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

#24 | 2016-09-15 ✅ Patent 9,999,653 granted on 2018-06-19
US20160263181A1
Human necessities

Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders

#25 | 2016-02-11 ✅ Patent 9,522,117 granted on 2016-12-20
US20160038424A1
Human necessities

Bromocriptine formulations

#26 | 2015-11-26 ✅ Patent 9,925,186 granted on 2018-03-27
US20150335641A1
Human necessities

Method of treating metabolic disorders and depression with dopamine receptor agonists

#27 | 2015-01-22 ✅ Patent 9,352,025 granted on 2016-05-31
US20150024995A1
Human necessities

Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

#28 | 2014-11-20 ✅ Patent 9,364,515 granted on 2016-06-14
US20140342975A1
Human necessities

Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders

#29 | 2014-09-04 ✅ Patent 10,137,132 granted on 2018-11-27
US20140249136A1
Human necessities

Parenteral formulations of dopamine agonists

#30 | 2014-07-03 ✅ Patent 9,192,576 granted on 2015-11-24
US20140187560A1
Human necessities

Bromocriptine formulations

#31 | 2014-01-30 ✅ Patent 9,205,084 granted on 2015-12-08
US20140031359A1
Human necessities

Method of treating metabolic disorders and depression with dopamine receptor agonists

#32 | 2013-10-31 ✅ Patent 8,613,947 granted on 2013-12-24
US20130287848A1
Human necessities

Bromocriptine formulations

#33 | 2013-08-01 ✅ Patent 9,415,005 granted on 2016-08-16
US20130197005A1
Human necessities

Parenteral formulations of dopamine agonists

#34 | 2013-04-30 ✅ Patent 8,431,155 granted on 2013-04-30
US13460452
-

Bromocriptine formulations

#35 | 2012-06-07 ✅ Patent 8,877,708 granted on 2014-11-04
US20120142582A1
Human necessities

Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders

#36 | 2012-05-24 ✅ Patent 8,821,915 granted on 2014-09-02
US20120129783A1
Human necessities

Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders

#37 | 2011-08-11 ✅ Patent 8,137,994 granted on 2012-03-20
US20110195971A1
Human necessities

Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof

#38 | 2011-08-11 ✅ Patent 8,137,993 granted on 2012-03-20
US20110195970A1
Human necessities

Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof

#39 | 2011-06-09 ✅ Patent 8,137,992 granted on 2012-03-20
US20110136817A1
Human necessities

Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof

#40 | 2010-02-11
US20100035886A1
Human necessities

PARENTERAL FORMULATIONS OF DOPAMINE AGONISTS

#41 | 2009-06-04 ✅ Patent 8,741,918 granted on 2014-06-03
US20090143390A1
Human necessities

Parenteral formulations of dopamine agonists

#42 | 2009-05-28
US20090137598A1
Human necessities

METHOD OF TREATING METABOLIC DISORDERS AND DEPRESSION WITH DOPAMINE RECEPTOR AGONISTS

#43 | 2008-11-27 ✅ Patent 9,655,865 granted on 2017-05-23
US20080293735A1
Human necessities

Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes

Also check out VeroScience LLC's (Tiverton, United States) applicant profile with 37 patent applications submitted.

AssigneeID:

32819 ⎘